Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument
Leveraging trusted automation from Leica Biosystems, the new offering helps researchers move from tissue sample to biological insight faster through more flexible, higher-plex immunofluorescence
Molecular Instruments® (MI), founded by the inventor of HCR™ technology, today announced the release of HCR™ Gold IF on the BOND RX research staining instrument from Leica Biosystems, a Danaher company and global leader in end-to-end anatomic and digital pathology solutions. This offering expands access to automated multiplex immunofluorescence workflows that help researchers move from tissue sample to biological insight faster and with greater flexibility.
HCR™ Gold IF enables flexible multiplex protein detection using off-the-shelf primary antibodies on the BOND RX stainer, an established automation platform. The assay supports the use of multiple primary antibodies from the same host species and isotype without stripping workflows, custom antibody conjugations, or reliance on predetermined panels—giving researchers a more practical path to higher-plex analysis without disrupting established workflows.
